Mycobacterium tuberculosis
Tuberculosis has afflicted mankind for thousands of years, and it is still the single most deadly infectious disease in developing countries. It is estimated that one-third of the world's population is or has been infected with Mycobacterium tuberculosis (24) . In 2000, nearly 9 million new tuberculosis cases were reported, and 3 million people died from this disease (41) . Current treatment for tuberculosis involves chemotherapy over the course of 6 months with several first-line antitubercular agents, isoniazid (isonicotinic acid hydrazide), rifampin, pyrazinamide, streptomycin, and ethambutol. Although proper prescription with full patient compliance is highly effective in curing pulmonary tuberculosis, the emergence of M. tuberculosis strains that are resistant to the firstline drugs represents a serious challenge to tuberculosis control. In the United States, about 13% of isolates from new tuberculosis cases are resistant to one or more of the first-line antitubercular drugs, and 1.6% of cases are resistant to both isoniazid and rifampin, defined as multidrug-resistant tuberculosis (22, 40) .
Since its discovery five decades ago (2, 5, 27, 29) , isoniazid has been commonly used to treat and prevent tuberculosis. Despite its importance, only recently has insight been gained into the molecular mechanism of isoniazid's action. It is now known that isoniazid is a prodrug (15) which is converted into a biologically active form by an M. tuberculosis catalase-peroxidase, KatG (44) . Mycolic acid synthesis is the primary pathway inhibited by the action of isoniazid (4, 33, 34, 39) . Mycolic acids are long-chain ␣-alkyl ␤-hydroxy fatty acids containing up to 90 carbons and are the major component of mycobacterial cell walls. Two enzymes involved in the biosynthesis of mycolic acids have been suggested to be the targets of KatG-activated isoniazid: the NADH-dependent enoyl-acyl carrier protein reductase (InhA) (1) and the ␤-ketoacyl acyl carrier protein synthase (designated KasA) (21) .
The crystal structure of isoniazid-inhibited InhA revealed that an isonicotinic acyl-NADH was bound to the active site of InhA (31) . It was later shown that the same isonicotinic acyl-NADH InhA inhibitor can be generated by either KatG-or Mn 2ϩ -mediated activation of isoniazid in vitro (16) . InhA binds this inhibitor with an affinity much higher than that for NADH, resulting in complete inactivation of InhA in vitro (16) . The interaction between KasA and isoniazid was implied by the recent discovery of a covalent complex of isoniazid, KasA, and its acyl carrier protein (AcpM) from isoniazidtreated M. tuberculosis (21) .
Although overexpression of the inhA gene and mutations of the InhA protein have been associated with isoniazid resistance (9, 25, 26) , the majority of clinical isolates of isoniazidresistant M. tuberculosis have mutations in the katG gene that do not occur in isoniazid-susceptible strains (7-9, 20, 23, 25, 26) . Many KatG mutations have been shown to be associated with a decrease in or abolition of catalase and peroxidase activities (8, 29, 30, 38, 43) . The most frequently encountered KatG mutation in clinical M. tuberculosis isolates is the substitution of serine for threonine at amino acid 315. This mutation of KatG resulted in about a 70% decrease in the catalase and peroxidase activities and a compromised ability to oxidize isoniazid to isonicotinic acid (32, 38) .
Catalase and peroxidase activities were commonly measured to assess the functional consequences of KatG mutations. However, a direct determination of the enzymatic activities of various KatG variants in generating the InhA inhibitor from isoniazid has rarely been carried out. Hence, many aspects of the role of KatG mutations in isoniazid resistance are not clear. In the work reported here, six katG mutations uniquely represented in isoniazid-resistant clinical isolates were introduced into the wild-type katG gene by site-directed mutagenesis. The corresponding mutant enzyme variants were expressed in Escherichia coli, purified, and characterized with respect to their catalase and peroxidase activities, rates of isoniazid oxidation, and, moreover, their abilities to activate isoniazid. The effect of Mn 2ϩ on isoniazid activation was also investigated.
MATERIALS AND METHODS

Materials.
Isoniazid, NADH, MnCl 2 , nitro blue tetrazolium (NBT), glucose oxidase (type II), ␦-aminolevulinic acid, and Sephadex G-25 were obtained from Sigma. H 2 O 2 and t-butyl hydroperoxide were products of Aldrich. DEAE-Sepharose Fast Flow, Q-Sepharose Fast Flow, phenyl-Sepharose Fast Flow, MonoQ HR 10/10, and Sephacryl S-300 HR were purchased from Amersham Pharmacia Biotech. All phosphate buffers were used at pH 7.0 and consisted of phosphate at mole fractions of 0.39 sodium monobase and 0.61 potassium dibase.
Site-directed mutagenesis. The katG coding region of pKAG3 (16) was modified by the QuickChange site-directed mutagenesis kit (Stratagene) with the primers 5Ј-CCGAGCAACACCCACCCATTACAGAAACCACCACC-3Ј and 5Ј-GGTGGTGGTTTCTGTAATGGGTGGGTGTTGCTCGG-3Ј to generate pKAG4. Single mutations of the wild-type katG gene in pKAG4 were obtained with the same kit. The mutations, mutation positions, and mutagenesis primers are summarized in Table 1 . All mutations were confirmed by DNA sequencing.
Protein expression and purification. Recombinant M. tuberculosis InhA was expressed and purified from pINA-transformed E. coli JM109 (16) . Wild-type and mutant KatG proteins were purified by fast protein liquid chromatography from KatG-deficient E. coli strain UM262 (recA katG::Tn10 pro leu rpsL hsdR endI lacY) (17) harboring the desired plasmid by the method of Lei et al. (16) with slight modifications. One modification was the supplementation of LuriaBertani broth with 50 M ␦-aminolevulinic acid, a heme biosynthesis intermediate, which was added to avoid the accumulation of KatG apoprotein (3). Additionally, the protein samples eluted from the DEAE-Sepharose Fast Flow column were applied to a Sephacryl S-300 HR column (2.6 by 60 cm) preequilibrated with 150 mM NaCl in 50 mM phosphate, pH 7.0, and eluted with the same buffer.
Enzyme assays. (19) . One unit of peroxidase activity catalyzes the oxidation of 1 mol of o-dianisidine per min at 23°C. In addition, rates of free-radical formation from isoniazid oxidation in the presence of a constant H 2 O 2 flux (generated by glucose and glucose oxidase) were monitored by following the reduction of NBT by the method of Hillar and Loewen (12) .
Isoniazid activation. Isoniazid activation by KatG was determined by the formation of InhA-inhibitor complex as described previously (16) . A 1-ml 50 mM phosphate solution containing 1 mM NADH, 1 mM isoniazid, and 0.5 M KatG was incubated for 3 h at room temperature under aerobic condition with or without 5 M MnCl 2 . KatG was separated from the reaction mixture by passing through a Microcon YM-10 filter unit with a molecular weight cutoff of 10,000 (Millipore). The filtrate (0.8 ml) was incubated with InhA (78.5 or 200 M in 0.2 ml) at room temperature for 30 min and then loaded on a Sephadex G-25 column (1 by 40 cm) preequilibrated and eluted with 50 mM phosphate. The gel filtration was repeated once, and the fractions containing InhA protein were collected.
The UV-visible absorption spectra of InhA-containing fractions were recorded with an SLM 3000 Array spectrophotometer. On the basis of the characteristic absorption spectral properties of the InhA-inhibitor complex, the amounts of InhA-bound inhibitor can be calculated with 7.1 and 7.2 mM Ϫ1 cm Ϫ1 for ε 291 and ε 326 , respectively, and concentrations of InhA can be determined by using 26.4 mM Ϫ1 cm Ϫ1 for ε 291 (16) . There was no detectable absorption at 326 nm for InhA (16) .
Miscellaneous measurements. KatG molar concentrations were calculated according to the heme contents determined by the pyridine hemochrome assay with ε 418 ϭ 191.5 mM Ϫ1 cm Ϫ1 (6). InhA protein concentrations were determined by the method of Lowry et al. (18) with bovine serum albumin as a standard. All data presented are the means Ϯ standard deviation of three measurements.
RESULTS
Recombinant KatG mutants.
Six katG alleles encoding KatG A110V, A139P, S315N, L619P, L634P, and D735A variants identified uniquely in isoniazid-resistant M. tuberculosis clinical isolates (28) were obtained by site-directed mutagenesis. All KatG variants were expressed in the KatG-deficient E. coli UM262 and purified to 50 to 90% homogeneity, based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Fig. 1 ). The addition of ␦-aminolevulinic acid to the cell growth medium greatly enhanced the production of KatG holoenzyme (3 (38) . KatG also has peroxidase activity with several substrates (14) . In this study, the oxidation rates of various levels of o-dianisidine were measured, and the kinetic parameters are shown in Table 3 . Compared to wild-type KatG, KatG A110V was 40% higher in k cat and 24% lower in K m , resulting in an 80% increase in k cat /K m . The other mutants had two-to fourfold-lower values of k cat /K m . Changes in K m were rather limited in value. Therefore, the observed decreases in k cat /K m were primarily a consequence of lower k cat values.
Isoniazid oxidation activity. KatG has also been shown to catalyze the oxidation of isoniazid (12, 13) . One assay for isoniazid oxidation by KatG in the presence of H 2 O 2 was developed by coupling the free radicals generated in the reaction with NBT reduction (12) . When wild-type KatG was tested in this assay, we noted a significant background activity of NBT reduction in the absence of isoniazid. However, the NBT reduction was substantially enhanced in the presence of isoniazid ( Fig. 2A) , allowing us to obtain the net isoniazid oxidation/NBT reduction time course after subtraction of the background activity (Fig. 2B) .
Five KatG variants were also assayed in the absence and presence of isoniazid, and their net isoniazid oxidation/NBT reduction time courses were obtained as described above. The time courses are shown in Fig. 2B for wild- Isoniazid activation by KatG. M. tuberculosis KatG catalyzes the activation of isoniazid to yield an InhA inhibitor. Only recently has a method for the direct detection and quantification of this InhA inhibitor been developed by using InhA to trap an inactive enzyme-inhibitor complex (16) . This InhAinhibitor complex has an absorption peak at 278 nm and a pronounced shoulder around 326 nm which can be used as an indicator for detection and quantification of InhA inhibitor formation (16) . With the wild-type and all mutant KatG proteins used for the activation of isoniazid, various degrees of formation of the InhA inhibitor (trapped in the form of the inhibitor-InhA complex) were detected, as shown by the various magnitudes of the absorption shoulder at 326 nm (Fig. 3 , Table 4 ). Compared to wild-type KatG, KatG A110V produced nearly the same level of the InhA inhibitor, whereas reduced yields of production were detected for KatG L634F KatG-mediated oxidation of isoniazid, followed by NBT reduction. All experiments were carried out at room temperature. To 1 ml of 50 mM phosphate buffer, KatG proteins, NBT, glucose oxidase, and glucose were added at 1 M, 0.2 mM, 5 mg, and 4 mM, respectively. (A) Time course of NBT reduction with and without the addition of 9 mM isoniazid (INH) with wild-type KatG. (B) Time courses of net isoniazid-dependent NBT reduction by wild-type KatG (WT) and three variants. For each KatG sample tested, NBT reduction in the absence of isoniazid was subtracted from that in the presence of isoniazid to obtain the net isoniazid-dependent NBT reduction over time. 
DISCUSSION
One of the most commonly occurring KatG variants, KatG L463R , was originally thought to be responsible for isoniazid resistance, but that strain was found to be fully active in isoniazid activation (14) , demonstrating the importance of biochemical studies on KatG mutants in relation to isoniazid resistance. However, only a few reports (8, 32, 37, 38, 42) have studied the relationship between isoniazid resistance and the catalase, peroxidase, and isoniazid oxidation activities and isoniazid binding to KatG mutants.
To investigate the biochemical link between specific mutations in the katG gene and isoniazid resistance, we generated, purified, and characterized six KatG variants present uniquely in isoniazid-resistant clinical isolates. Three mutants (KatG A139P , KatG L634F , and KatG D735A ) had significantly diminished isoniazid activation activities. Two other mutants (KatG S315N and KatG L619P ) failed to convert isoniazid into the InhA inhibitor. Hence, we demonstrated biochemically that certain single-residue amino acid replacements can completely abolish the ability of KatG to produce the InhA inhibitor. On the other hand, KatG A110V was 88% as active as wild-type KatG in isoniazid activation. Therefore, these six KatG mutants had a wide range of abilities to produce the InhA inhibitor.
In addition to isoniazid activation, we also compared these KatG variants with wild-type KatG with respect to their catalase, peroxidase, and isoniazid oxidation activities. On the basis of relative activity, defined as the ratio of mutant KatG activity to wild-type KatG activity, a summary of such comparisons is shown in Fig. 4 . With the exception of KatG A110V (which showed substantially higher peroxidase activity), the catalase activities of all other KatG mutants correlated quite well with their peroxidase activities. However, no consistent pattern emerged from the correlations of catalase-peroxidase activities with isoniazid activation activities. The relative isoniazid activation activities of KatG A110V and KatG D735A correlated well with their catalase activities and, in the latter case, peroxidase activity. However, in comparison with the catalase- peroxidase   FIG. 3 . Isoniazid activation by wild-type and mutant KatG. The reactions were carried out for 3 h at room temperature with a sample of 1 ml of 50 mM phosphate, pH 7.0, containing 1 mM isoniazid, 1 mM NADH, and 0.5 M wild-type KatG or a A110V, A139P, S315N, L619P, L634F, or D735A KatG mutant. KatG was then removed with Micron YM-10 filter units. One milliliter of sample containing 0.8 ml of filtrate and 0.2 ml of 78.5 M InhA was incubated at room temperature for 20 min. The mixture was subjected to Sephadex G-25 column filtration twice, and the InhA-inhibitor complex was isolated. The spectra were normalized to a content of 10 M InhA. (A) Absorption spectrum of the InhA-inhibitor complex with wild-type KatG for isoniazid activation. (B) Absorption spectrum of the same InhAinhibitor complex derived from wild-type KatG (WT) activation of isoniazid is reproduced for the range of 300 to 400 nm. This spectrum is compared with those obtained under identical conditions with either the L634F or S315N KatG mutant in place of wild-type KatG. The final spectrum obtained for a negative control, in which wild-type KatG was used but no isoniazid was added, under otherwise identical conditions was identical to that shown for the S315N KatG mutant. For simplicity, spectra obtained with the other KatG mutants are not included. The corresponding yields of the inhibitor derived from isoniazid activation by all KatG species tested were calculated from the spectral data so obtained and are presented in Table 4 .
FIG. 4. Comparison of enzyme activities of KatG mutants with
wild-type KatG. Results of catalase (E), peroxidase (ᮀ), isoniazid oxidation/NBT reduction (‚), and isoniazid activation in the absence of Mn 2ϩ (F) activity determinations described in the text were used to calculate the relative activities, defined as the ratios of KatG mutant activity to wild-type KatG activity. The relative activities of isoniazid oxidation/NBT reduction were also measured for five KatG variants, which showed a generally better but still inconsistent correlation with their isoniazid activation activities. A good correlation was found for KatG A110V . While KatG A139P and KatG D735A were about 25% as active as the wild type and KatG S315N and KatG L619P were inactive in isoniazid activation, they all showed about 6 to 9% of wild-type activity in isoniazid oxidation/NBT reduction. These findings indicate that, in biochemical characterization of KatG mutants, isoniazid activation activities should be determined directly rather than by inference from catalase, peroxidase, or isoniazid oxidation/NBT reduction activities.
Like other bacterial catalase-peroxidase enzymes (36), mycobacterial KatG is believed to consist of three domains, a 54-residue N-terminal domain, a heme-binding catalytic domain (residues 55 to 423), and a C-terminal domain (residues 424 to 740) (10) . The A110, S315, L634, and D735 residues are conserved among KatG catalases from E. coli, Salmonella enterica serovar Typhimurium, Streptomyces reticuli, Bacillus stearothermophilus, Mycobacterium bovis, Mycobacterium intracellulare, Mycobacterium smegmatis, and M. tuberculosis. The L619 residue is also conserved among these species except for M. intracellulare, in which it is replaced by a valine residue. The A139 residue is conserved in the cytochrome c peroxidase of Saccharomyces cerevisiae and KatG of B. stearothermophilus, M. bovis, M. intracellulare, M. semgmatis, and M. tuberculosis, whereas it is replaced by valine in E. coli and S. enterica serovar Typhimurium KatG. Therefore, the six KatG variants from isoniazid-resistant M. tuberculosis isolates all carry a single mutation of a conserved residue. However, three residues (A110V, A139P, and S315N) are located in the catalytic/hemebinding domain, whereas three other residues (L619P, L634F, and D735A) are in the functionally undefined C-terminal domain.
Within the C-terminal domain, mutation R463L or L587M has no detectable effect on KatG enzymatic properties (14, 32) or, in the former case, the ability to activate isoniazid (14) . However, the mutation L587P in both M. tuberculosis and M. bovis results in instability and inactivation of the KatG protein (32) . We found that the catalase, peroxidase, isoniazid oxidation, and activation activities of KatG L619P , KatG L634F , and KatG D735A were all variously affected by their mutations. These and earlier findings together suggest that the C-terminal domain plays a role in stabilizing subunit-subunit interactions (32) but may also be important for KatG enzyme function.
For the three residues in the catalytic domain, the A110V substitution did not dramatically alter the enzymatic activities, suggesting that A110 is not directly involved in heme or substrate binding. The replacement of serine at position 315 of KatG with threonine, asparagine, arginine, glycine, or isoleucine has been identified in clinical isoniazid-resistant M. tuberculosis isolates. Both the catalase-peroxidase activities and the ability to oxidize isoniazid to isonicotinic acid are compromised in the most frequent variant, S315T (32, 38) . KatG S315N has now been found to be inactive in isoniazid activation, suggesting that the isoniazid resistance of the other KatG S315 mutants may also be a consequence of their inability to generate the InhA inhibitor. The M. tuberculosis KatG A139 residue is equivalent to the A83 residue of yeast cytochrome c peroxidase, which is in a loop near the heme-binding site (35 
